Vabysmo

Chemical Namefaricimab-svoa
Dosage FormInjection (intravitreal; 120 mg/Ml)
Drug ClassInhibitors
SystemOcular
CompanyGenentech
Approval Year2022

Indication

  • For the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (nAMD)
  • For the treatment of patients with Diabetic Macular Edema (DME)
Last updated on 2/11/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Vabysmo (faricimab-svoa) Prescribing Information. 2022Genentech, Inc., South San Francisco, CA